



Farxiga (dapagliflozin) and Jardiance (empagliflozin) are Sugar-Glucose Co-Transporter (SGLT2) now approved for cardiac patients to reduce hospitalization for heart failure and the risk of cardiovascular death.

While taking this medication:

- *Please contact your primary care provider and endocrinologist (if you have one) to see if any of your non cardiac meds need to change.

- *Continue taking all your current cardiac medications.

- *If you are having surgery, contact your primary care provider and surgeon to see if you need to discontinue 3 days prior to surgery

Things to watch for after starting the medication:

- *Increased urination- communicate with our clinic for excessive urination, low blood pressure, or fatigue.

- *Urinary tract infections (UTI's) – report burning on urination, fever, chills, and fatigue promptly

- *Low blood sugar – common symptoms - sweating, feeling “jittery”, trouble concentrating, fatigue, and hunger

- *Infection in the genital area – common symptoms include redness, irritation, itching, and pain

Type I Diabetics or Pregnant Patients should not take these medications